Showing results (101-110 of 440) with videos related to

Sort By:
Pageof 44
Biochemical Pharmacology|May 9, 2002
Verapamil decreases glucuronidase activity in the gutJörn Lötsch, Bernhard Sperker, Heyo K Kroemer, et al.
Trends in Molecular Medicine|November 28, 2018
Ceramides as Novel Disease BiomarkersJennifer Kurz, Michael J Parnham, Gerd Geisslinger, et al.
Journal of the National Cancer Institute|June 8, 2006
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitorsSabine Grösch, Thorsten Jürgen Maier, Susanne Schiffmann, et al.
Pharmacology & Therapeutics|February 14, 2019
Potential biomarkers for persistent and neuropathic pain therapyMarco Sisignano, Jörn Lötsch, Michael J Parnham, et al.
Pharmacology & Therapeutics|November 14, 2012
NOXious signaling in pain processingWiebke Kallenborn-Gerhardt, Katrin Schröder, Gerd Geisslinger, et al.
Human Genetics|September 20, 2015
Computational functional genomics based analysis of pain-relevant micro-RNAsJörn Lötsch, Ellen Niederberger, Alfred Ultsch
Plos One|December 24, 2011
Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injuryRuirui Lu, Wiebke Kallenborn-Gerhardt, Gerd Geisslinger, et al.
Drug Discovery Today|July 12, 2020
Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implicationsMarco Sisignano, Dieter Steinhilber, Michael J Parnham, et al.
Clinical Pharmacology and Therapeutics|September 13, 2005
The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depressionJörn Lötsch, Carsten Skarke, Andreas Schneider, et al.
Diabetes|April 28, 2005
Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healingHeiko Kämpfer, Ronald Schmidt, Gerd Geisslinger, et al.
Pageof 44